Navigation Links
Acutus Medical, Inc. Raises $21 Million Toward its B-Series Financing
Date:6/25/2013

SAN DIEGO, June 25, 2013 /PRNewswire/ -- Acutus Medical, Inc. (ACM), a medical device company developing a minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system for the identification of the sources that cause and/or sustain complex cardiac arrhythmias, including atrial fibrillation, announced it has completed an initial closing of $21 million towards its Series B financing round.  The round was led by new investor OrbiMed with the participation of existing investors. Proceeds will be primarily used to support the continued efforts in company's research and development, including clinical studies.

(Logo: http://photos.prnewswire.com/prnh/20130430/LA01948LOGO)

"We are very pleased to be working with our new investors as well as our current team as we continue our passion to develop the first clinical evidence-based system using 3D Cardiac Chamber Imaging and Dipole Density Mapping to identify the issues causing irregular heart rhythms, no matter the cause, then help physicians treat each patient's needs while reducing costs to providers and the healthcare system," said Randy Werneth, CEO of Acutus Medical.

"With investors like Index Ventures, Advent Ventures and now OrbiMed Ventures who all have a long track record of building great companies around transformative innovations, we believe this financing will support an exciting next chapter in advancing the technology of Acutus Medical to become the only system capable of mapping the source of all arrhythmias regardless of mechanism or substrate.  With CT-quality imaging and Dipole Density-based activation, the combined information should make for more efficient procedures by identifying precise treatment targets, monitoring therapy progress, and identifying the clinical impact on the patient – all in real-time," sa
'/>"/>

SOURCE Acutus Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
2. Acutus Medical, Inc. lance la première étude clinique sur lhomme dun cathéter à imagerie 3D en temps réel offrant une qualité comparable aux TDM/IRM
3. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
4. Astute Medical, Inc. patrocinerà il simposio informativo presso il meeting sulla nefrologia in terapia intensiva
5. Astute Medical, Inc., veranstaltet Symposium aus anlaß des Critical Care Nephrology Kongress
6. Astute Medical, Inc. va accueillir un symposium éducatif lors dune réunion dédiée à la réanimation néphrologique
7. Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc.
8. Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference
9. Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices
10. Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt
11. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... industry is expecting a busy summer this year, and ... Day weekend, more hotels and resorts are raising their ... according George Clarke, CEO of UMF Corporation, a developer ... hotels and resorts adopting environmental hygiene practices developed for ...
... SAN FRANCISCO, May 22, 2012  Boehringer Ingelheim announced ... the investigational compound tiotropium delivered once-daily via the ... moderate persistent asthma. The data were presented at ... Society (ATS 2012). Boehringer Ingelheim announced that a ...
Cached Medicine Technology:With Busy Summer Forecast Ahead, More Hotels Are Raising Hygiene Standards, Says UMF Corporation 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 2Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 3Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma 4
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... enzyme pathway that helps prevent new cells from receiving ... has been directly linked to cancer and other diseases. ... near the end of cell division, the enzyme Cdc14 ... DNA are fully repaired before the parent cell distributes ... helps safeguard against some of the most devastating genome ...
(Date:4/23/2014)... In science, "simple and accessible detection methods that ... the resolution of a single cell inside that ... chemical engineer Chang Lu. , In the Royal ... Lu has announced that he and his coworkers ... subcellular location of a protein ( Chem. Sci. ...
Breaking Medicine News(10 mins):Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... Revenue Up 16% ... Cellulite Product Launch Targeted for Late Q1 ... Company Updates Guidance for Full Year 2007, HAYWARD, Calif., Nov. 6 ... the aesthetic,industry, today reported its financial results for the third quarter ended,September 30, ...
... Organizations Rapidly Identify High-Risk Cases, Provide ... BIRMINGHAM, Ala., Nov. 6 The ... DST Health Solutions announced that 16,organizations have ... helps organizations rapidly identify at-risk patients for,care ...
... - Continued progress in both core business segments supports ... Corporation,(Nasdaq: VRNM ), a leading developer of technologies ... of high-performance specialty,enzymes, today reported financial results for the ... "We are very pleased with the progress the Company ...
... Mass., Nov. 6 Biopure Corporation,(Nasdaq: BPUR ... public,offering of stock and warrants that raised net ... exercise of the warrants. Biopure,sold 19,377,500 new shares ... an,additional 19,377,500 shares, including 2,527,500 shares and 2,527,500,warrants ...
... group says , TUESDAY, Nov. 6 (HealthDay News) -- Standard ... been proposed by a team of Johns Hopkins experts, who ... comparisons and help improve patient safety. , "Hospitals are ... this is long overdue, the data is only helpful if ...
... for patients with sudden, life-threatening attacks, trial shows , , ... kind of medication has failed as treatment for the ... trial finds. , The drug, tezosentan, did not improve ... or cut their risk of death after acute ...
Cached Medicine News:Health News:Thermage Announces Third Quarter Financial Results 2Health News:Thermage Announces Third Quarter Financial Results 3Health News:Thermage Announces Third Quarter Financial Results 4Health News:Thermage Announces Third Quarter Financial Results 5Health News:Thermage Announces Third Quarter Financial Results 6Health News:Thermage Announces Third Quarter Financial Results 7Health News:Thermage Announces Third Quarter Financial Results 8Health News:Thermage Announces Third Quarter Financial Results 9Health News:Sixteen Organizations Implement ACG Rx-PM Predictive Modeling from Johns Hopkins University, DST Health Solutions 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 8Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 9Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 10Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 11Health News:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007 12Health News:Experimental Drug Fails Against Heart Failure 2Health News:Experimental Drug Fails Against Heart Failure 3
... latest in the Magnes line of biomagnetometer systems, ... full cortical coverage, provides the highest detector density ... of a wide range of neuronal activity. The ... detector configurations and can be equipped with radial ...
... for basic and advanced NCS, ... large 12.1" XGA (1024 x ... the latest in technology allow ... advanced NCS capabilities, advanced EMG ...
... is a non-invasive and painless method of ... Cadwell Laboratories manufactures two magnetic stimulation devices, ... Stimulator (HSMS). The Hight Speed MES-10 magnetic ... to 25 Hz at full power. Several ...
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
Medicine Products: